JanOne to Present Data On Its Two Non-Opioid Drug Candidates at The Appalachian Region Spine and Pain Meeting on Drug Development Programs to Treat Pain on April 15, 2023
JanOne (Nasdaq: JAN), represented by Dr. Amol Soin, will present at the Appalachian Region Spine and Pain Meeting on April 15, 2023, discussing innovation in pain medicine and the company’s drug development programs. JanOne focuses on non-opioid treatments for pain management, introducing two late-stage drug candidates: JAN 101, aimed at treating peripheral artery disease and diabetic neuropathy, and JAN 123, a low-dose naltrexone for Complex Regional Pain Syndrome, which received orphan drug status from the FDA. Dr. Soin aims to highlight the need for effective pain management solutions amid the opioid crisis, which underscores JanOne's commitment to developing non-addictive medication options. The meeting will serve as a platform to engage physicians seeking alternatives to opioids.
- None.
- None.
LAS VEGAS, April 13, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), Dr. Amol Soin, Chief Medical Officer of JanOne, will be presenting at the Appalachian Region Spine and Pain Meeting in Sulfur Springs, West Virginia on Saturday, April 15th on the topic of Innovation in Pain Medicine and will be discussing the drug development programs at JanOne. JanOne is a biotech company that is developing two different late-stage non-opioid drug candidates: JAN 101 is designed to treat peripheral artery disease that was also shown to improve pain in patients with diabetic neuropathy in a phase II study and JAN 123 which is low dose naltrexone to treat Complex Regional Pain Syndrome. JAN 123 was granted orphan drug status by the FDA.
"I look forward to presenting our research programs and drug candidates from JanOne which I hope will provide two new non opioid based pain medications to treat complex regional pain syndrome and potentially pain from peripheral artery disease", noted Dr Amol Soin.
The Appalachian Spine and Pain Meeting is a forum attended mostly by pain management physicians to learn and discuss new and innovative treatments. JanOne is working to develop multiple medications to help treat pain without addiction. "The opioid crisis really impacted this country and we realized what is needed are new options to treat pain without opioids. We look forward to developing these products so doctors have the tools they need to treat pain without addiction", noted Tony Isaac CEO of JanOne.
"Pain physicians have been actively searching for new non-opioid medications to treat chronic pain. The scientific discussions I will have at this meeting will help to solidify our development plans and will hopefully soon bring relief to patients." said Dr Amol Soin.
Forward Looking Statements
This press release contains statements that are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to the statements that JAN 101 will treat PAD, that JAN 123 will treat CRPS, the timing of the commencement of further clinical trials, that the FDA will permit approval through a 505(b)(2) pathway for JAN 123, that upon approval JAN 101 will immediately disrupt the PAD market, and other statements, including words such as "continue", "expect", "intend", "will", "hope" "should", "would", "may", "potential" and other similar expressions. Such statements reflect JanOne's current view with respect to future events, are subject to risks and uncertainties, and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by JanOne, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause JanOne's actual results, performance or achievements to be materially different from any future results, performance or achievements described in this press release. Such factors could include, among others, those detailed in the Company's periodic reports filed with the Securities and Exchange Commission (the "SEC").
Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled "Risk Factors" in JanOne's filings with the SEC underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and JanOne does not intend, and does not assume any obligation, to update these forward-looking statements, except as required by law. JanOne cannot assure that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Individuals are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.
About JanOne Inc.
JanOne is a unique Nasdaq-listed company offering innovative, actionable solutions that it believes can help end the opioid crisis. JanOne is dedicated to funding resources toward innovation, technology and education to find a key resolution to the national opioid epidemic, which is one of the deadliest and most widespread in the nation's history. Its drugs in the clinical trial pipeline have shown promise for their innovative targeting of the causes of pain as a strategic option for physicians averse to exposing patients to addictive opioids.
Please visit www.janone.com for additional information.
Media Contact
Investor Relations
IR@janone.com
1-800-400-2247
View original content to download multimedia:https://www.prnewswire.com/news-releases/janone-to-present-data-on-its-two-non-opioid-drug-candidates-at-the-appalachian-region-spine-and-pain-meeting-on-drug-development-programs-to-treat-pain-on-april-15-2023-301796469.html
SOURCE JanOne Inc.
FAQ
What is the purpose of JanOne's presentation at the Appalachian Region Spine and Pain Meeting on April 15, 2023?
What are JanOne's two main drug candidates and their intended uses?
What recent designation did JAN 123 receive from the FDA?
Who is presenting on behalf of JanOne at the meeting?
Why are non-opioid pain medications important according to JanOne's CEO?
